Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

Background: Administration of subcutaneous (SC) bortezomib in patients with multiple myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient evidence to support the use of SC bortezomib as a standard of care. Methods: A systematic review of 4 randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ziqi, Chen, Jie, Xuan, Zixue, Yang, Wenchao, Chen, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529723/
https://www.ncbi.nlm.nih.gov/pubmed/31190749
http://dx.doi.org/10.2147/DDDT.S198117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529723/
https://www.ncbi.nlm.nih.gov/pubmed/31190749
http://dx.doi.org/10.2147/DDDT.S198117

Ejemplares similares